Pacific Biosciences of Californ vs Pfizer, Inc. — Stock Comparison

PACB
Pacific Biosciences of Californ
$1.60
▲ 0.63%
vs
PFE
Pfizer, Inc.
$26.33
▼ 1.39%
Q·Score Winner
Pfizer, Inc.
PFE6.5/10vs 5.5/10

Q·Score Breakdown

5.5
Neutral
Overall
6.5
Neutral
3.4
Quality
7.4
5.7
Health
7
7.3
Growth
5.6
6.4
Valuation
6.7
5.2
Sentiment
5.2
PACB

Revenue expanding at 14% year-over-year.

low return on equity (-213%).

PFE

Strong profitability with 12% net profit margins.

analyst sentiment is cautious.

Analyst Consensus

HOLD
Target $2.38 (+48.4%)
6 analysts
HOLD
Target $29.00 (+10.2%)
27 analysts

Fundamentals

PACB
PFE
Trailing P/E
19.4×
-3.8×
Forward P/E
9.4×
0.0%
Profit Margin
12.4%
34.3%
Gross Margin
75.8%
-213.5%
ROE
8.9%
13.8%
Revenue Growth
-1.2%
Earnings Growth
2.33
Beta
0.39
Price / Book
$497M
Market Cap
$149.8B
$1 – $3
52-Week Range
$22 – $29

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →